Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

281.41 -9.68 (-3.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
52 53 Next >
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors
Via Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
A Rough Start To 2024 What Might Be In Store For The Rest Of 2024?
The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year. 
Via Talk Markets
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
Via Benzinga
Is NASDAQ:AMGN a Good Fit for Dividend Investing?
Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors. 
Via Chartmill
Spotlight on Amgen: Analyzing the Surge in Options Activity
Via Benzinga
Looking Into Amgen's Recent Short Interest
Via Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now. 
Via InvestorPlace
Did Santa Claus Claus Leave Town A Day Early?
With the exception of the Dow, stocks are down hard to begin the new calendar year. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024
Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with. 
Via The Motley Fool
Topics ETFs Retirement
Exposures Pension
In-Depth Examination Of 18 Analyst Recommendations For Amgen
Via Benzinga
Is Amgen Stock a Buy Now?
Boring businesses can be successful, too. 
Via The Motley Fool
Amgen Stock Sees Relative Strength Rating Improve To 74
Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74. 
Via Investor's Business Daily
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug  
Via Benzinga
Exposures Product Safety
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone." 
Via InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
Amgen, Inc. (NASDAQ: AMGN) shares have been in focus amid developments in the AI-powered healthcare space. 
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.